GLMD
NASDAQ · Biotechnology
Galmed Pharmaceuticals Ltd
$3.63
+0.13 (+3.57%)
Open$3.67
Previous Close$3.50
Day High$3.80
Day Low$3.45
52W High$13.20
52W Low$3.27
Volume—
Avg Volume61.7K
Market Cap4.00M
P/E Ratio—
EPS$-12.13
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+375.9% upside
Current
$3.63
$3.63
Target
$17.25
$17.25
$9.83
$17.25 avg
$23.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.77M | 1.41M |
| Net Income | 137.6K | 142.0K | 102.7K |
| Profit Margin | 8.1% | 8.0% | 7.3% |
| EBITDA | 176.3K | 217.6K | 150.4K |
| Free Cash Flow | 176.3K | 155.0K | 130.1K |
| Rev Growth | +12.1% | -7.4% | -2.7% |
| Debt/Equity | 1.54 | 1.34 | 1.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |